Gail S. Wright

6.5k total citations · 1 hit paper
19 papers, 3.6k citations indexed

About

Gail S. Wright is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Gail S. Wright has authored 19 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Reproductive Medicine. Recurrent topics in Gail S. Wright's work include Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). Gail S. Wright is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). Gail S. Wright collaborates with scholars based in United States, Serbia and Croatia. Gail S. Wright's co-authors include Hope S. Rugo, Seock‐Ah Im, Carlos H. Barrios, Amreen Husain, Véronique Dièras, Hiroji Iwata, Sherene Loi, Volkmar Henschel, Roel Funke and Jane Yuet Ching Hui and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Gail S. Wright

16 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

2018 3.0k citations Peter Schmid, Sylvia Adams et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gail S. Wright United States	13	2.7k	1.1k	920	817	720	19	3.6k
Andreas Schneeweiss United States	2	2.4k 0.9×	852 0.8×	889 1.0×	731 0.9×	559 0.8×	3	3.0k
Gursel Aktan United States	22	2.5k 0.9×	858 0.8×	740 0.8×	787 1.0×	563 0.8×	52	3.1k
Kun He United States	27	2.0k 0.7×	1.3k 1.1×	578 0.6×	475 0.6×	835 1.2×	53	3.2k
Andreas Pircher Austria	27	1.5k 0.5×	855 0.8×	871 0.9×	931 1.1×	1.7k 2.3×	103	3.4k
Sigve Andersen Norway	33	2.0k 0.7×	1.2k 1.1×	981 1.1×	1.4k 1.7×	1.6k 2.2×	80	3.9k
Zaoqu Liu China	32	1.2k 0.4×	1.2k 1.1×	826 0.9×	1.1k 1.3×	1.5k 2.1×	142	3.4k
Jennifer R. Diamond United States	26	2.0k 0.7×	756 0.7×	466 0.5×	469 0.6×	998 1.4×	136	3.0k
Maria Vittoria Dieci Italy	36	3.1k 1.1×	1.1k 1.0×	750 0.8×	1.6k 1.9×	1.1k 1.5×	154	4.5k
Ariel López-Chávez United States	18	2.8k 1.0×	1.9k 1.7×	575 0.6×	465 0.6×	821 1.1×	41	3.7k
Shunchang Jiao China	30	1.9k 0.7×	977 0.9×	618 0.7×	655 0.8×	1.1k 1.6×	144	3.4k

Countries citing papers authored by Gail S. Wright

Since Specialization

Citations

This map shows the geographic impact of Gail S. Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail S. Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail S. Wright more than expected).

Fields of papers citing papers by Gail S. Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail S. Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail S. Wright. The network helps show where Gail S. Wright may publish in the future.

Co-authorship network of co-authors of Gail S. Wright

This figure shows the co-authorship network connecting the top 25 collaborators of Gail S. Wright. A scholar is included among the top collaborators of Gail S. Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail S. Wright. Gail S. Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Krivak, Thomas C., Gail S. Wright, Erika Hamilton, et al.. (2025). A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecologic Oncology. 199. 96–102.

Damodaran, Senthil, Fabrice André, Nisha Unni, et al.. (2024). Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification. Cancer Research. 84(9_Supplement). RF01–4. 5 indexed citations

Krivak, Thomas C., Gail S. Wright, Erika Hamilton, et al.. (2022). OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology. 166(2). 219–229. 44 indexed citations

Krivak, Thomas C., Gail S. Wright, Erika Hamilton, et al.. (2022). OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039). Gynecologic Oncology. 166. S27–S28.

Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2021). Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clinical Cancer Research. 28(4). 629–636. 28 indexed citations

O’Shaughnessy, Joyce, Gail S. Wright, Anu Thummala, et al.. (2021). Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial. Cancer Research. 81(4_Supplement). PD1–6. 6 indexed citations

Krivak, Thomas C., Gail S. Wright, Erika Hamilton, et al.. (2021). Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology. 162. S17–S17. 13 indexed citations

Vahdat, Linda T., Peter Schmid, Andres Forero‐Torres, et al.. (2021). Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. npj Breast Cancer. 7(1). 57–57. 39 indexed citations

Rugo, Hope S., Seock‐Ah Im, Fátima Cardoso, et al.. (2020). Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Cancer Research. 80(4_Supplement). GS1–2. 28 indexed citations

10.

Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2019). Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. The Lancet Oncology. 20(11). 1587–1601. 86 indexed citations

11.

O’Shaughnessy, Joyce, Gail S. Wright, Michael Danso, et al.. (2019). Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial. Annals of Oncology. 30. v860–v861.

12.

O’Shaughnessy, Joyce, Angela DeMichele, X. Cynthia, et al.. (2018). A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment. 170(3). 547–557. 35 indexed citations

13.

Schmid, Peter, Sylvia Adams, Hope S. Rugo, et al.. (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 379(22). 2108–2121. 3005 indexed citations breakdown →

14.

Moulder, Stacy, Denise A. Yardley, Gail S. Wright, et al.. (2018). Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study. Cancer Research. 78(13_Supplement). CT107–CT107. 3 indexed citations

15.

Seidman, Andrew D., Alison Conlin, Ariadne M. Bach, et al.. (2013). Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer. 13(4). 239–246.e1. 29 indexed citations

16.

Karp, Daniel D., Sandra J. Lee, Steven M. Keller, et al.. (2013). Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597. Journal of Clinical Oncology. 31(33). 4179–4187. 82 indexed citations

17.

Herzog, Cynthia E., Tanya Trippett, Joseph F. Grippo, et al.. (2010). Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors. Clinical Cancer Research. 17(3). 611–619. 41 indexed citations

18.

Reynolds, Craig H., Coleman K. Obasaju, Michael J. Schell, et al.. (2009). Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(34). 5808–5815. 138 indexed citations

19.

Wright, Gail S. & Michael E. Gruidl. (2000). Early detection and prevention of lung cancer. Current Opinion in Oncology. 12(2). 143–148. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact